Sanofi Pasteur announces Fluzone High-Dose vaccine effective for elderly
"We are pleased that this study demonstrates the superior relative efficacy of Fluzone High-Dose vaccine compared to Fluzone vaccine in preventing influenza in older adults," Sanofi Vice President of U.S. Scientific and Medical Affairs David P. Greenberg said. "This efficacy trial complements the previous evidence of superior immune responses for Fluzone High-Dose vaccine compared to Fluzone vaccine and reaffirms the Phase III safety data in this population that were the basis for FDA licensure of Fluzone High-Dose vaccine in 2009."
In the study, the Fluzone High-Dose vaccine proved to be 24.2 percent more effective than the Fluzone vaccine in preventing influenza in people 65 years and older. The research team conducting the study hypothesized that Fluzone High-Dose vaccine would be more effective than Fluzone due to previous clinical trials.
"Influenza vaccines have been shown to offer public health benefits in preventing influenza and its complications in all age groups; however, older adults still have the highest rates of influenza-related hospitalization and death despite having high immunization rates," Sanofi Senior Vice President of Research and Development John Shiver said. "This led Sanofi Pasteur to develop Fluzone High-Dose vaccine, which this trial has confirmed provides better protection against influenza compared to Fluzone vaccine in people 65 years of age and older."
Further trials will be conducted to determine how the vaccine fights against different influenza strains.